CALGARY, Aug. 30 /CNW/ - Stem Cell Therapeutics Corp. (TSX-V:SSS), a
Canadian biotechnology company engaged in treating certain central nervous
system disorders by stimulating endogenous neural stem cells, announced today
the release of a video interview with Dr. Steven Cramer, the Principal
Investigator of the company's Phase IIa clinical trial. In the interview
Dr. Cramer, a leading stroke specialist at the University of California,
Irvine, discusses his views on the company's lead therapy, NTx(TM)-265, in
development with regard to its potential benefit to patients suffering recent
stroke. NTx(TM)-265 is a candidate treatment regimen comprised of human
chorionic gonadotropin (hCG) and erythropoietin (EPO) administered
systemically.
